HK1200820A1 - 作為 調節劑的吡唑氨基嘧啶衍生物 - Google Patents

作為 調節劑的吡唑氨基嘧啶衍生物

Info

Publication number
HK1200820A1
HK1200820A1 HK15101249.0A HK15101249A HK1200820A1 HK 1200820 A1 HK1200820 A1 HK 1200820A1 HK 15101249 A HK15101249 A HK 15101249A HK 1200820 A1 HK1200820 A1 HK 1200820A1
Authority
HK
Hong Kong
Prior art keywords
lrrk2
modulators
aminopyrimidine derivatives
pyrazole
pyrazole aminopyrimidine
Prior art date
Application number
HK15101249.0A
Other languages
English (en)
Inventor
查爾斯.貝克-格倫
丹尼爾.喬恩.伯狄克
馬克.錢伯斯
布賴恩.
.尚
陳慧芬
安東尼.埃斯特拉德
扎卡里.凱文.斯威尼
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1200820A1 publication Critical patent/HK1200820A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15101249.0A 2012-05-03 2015-02-05 作為 調節劑的吡唑氨基嘧啶衍生物 HK1200820A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642019P 2012-05-03 2012-05-03
PCT/EP2013/058939 WO2013164321A1 (en) 2012-05-03 2013-04-30 Pyrazole aminopyrimidine derivatives as lrrk2 modulators

Publications (1)

Publication Number Publication Date
HK1200820A1 true HK1200820A1 (zh) 2015-08-14

Family

ID=48325675

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101249.0A HK1200820A1 (zh) 2012-05-03 2015-02-05 作為 調節劑的吡唑氨基嘧啶衍生物

Country Status (11)

Country Link
US (1) US9212173B2 (zh)
EP (1) EP2844652B1 (zh)
JP (1) JP6218808B2 (zh)
KR (1) KR102091894B1 (zh)
CN (2) CN106220615A (zh)
BR (1) BR112014026952B1 (zh)
CA (1) CA2870049C (zh)
HK (1) HK1200820A1 (zh)
MX (1) MX363118B (zh)
RU (1) RU2637947C2 (zh)
WO (1) WO2013164321A1 (zh)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871375C (en) * 2012-05-03 2020-10-27 F. Hoffmann-La Roche Ag Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
AU2014369031A1 (en) 2013-12-20 2016-07-07 Signal Pharmaceuticals, Llc Substituted Diaminopyrimidyl Compounds, compositions thereof, and methods of treatment therewith
EA029774B1 (ru) 2014-01-29 2018-05-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
JP6474826B2 (ja) 2014-01-29 2019-02-27 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 化合物
US20170226081A1 (en) * 2014-07-24 2017-08-10 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
JP6873980B2 (ja) 2015-09-14 2021-05-19 ファイザー・インク LRRK2阻害薬としての新規のイミダゾ[4,5−c]キノリンおよびイミダゾ[4,5−c][1,5]ナフチリジン誘導体
WO2017087905A1 (en) * 2015-11-20 2017-05-26 Denali Therapeutics Inc. Compound, compositions, and methods
CN108934162A (zh) 2015-12-16 2018-12-04 南方研究所 吡咯并嘧啶化合物、作为激酶lrrk2抑制剂的用途及其制备方法
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
HUE056678T2 (hu) 2016-06-16 2022-02-28 Denali Therapeutics Inc Pirimidin-2-ilamino-1H-pirazolok mint LRRK2 inhibitorok neurodegeneratív rendellenességek kezelésére való alkalmazásra
CN106588884B (zh) * 2016-11-10 2019-04-09 浙江大学 2-多取代芳环-嘧啶类衍生物及制备和医药用途
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
BR112019028205A2 (pt) * 2017-06-30 2020-10-06 Amgen Inc. síntese de omecamtiv mecarbil
MA51222A (fr) 2017-11-21 2020-10-07 Denali Therapeutics Inc Polymorphes et formes solides d'un composé de pyrimidinylamino-pyrazole, et procédés de production
CA3086182A1 (en) 2017-12-20 2019-06-27 Denali Therapeutics Inc. Process for the preparation of pyrimidinyl-4-aminopyrazole compounds
JP7364841B2 (ja) * 2018-02-14 2023-10-19 智彦 大和田 酸ハロゲン化物による化合物の製造方法
WO2019159248A1 (ja) 2018-02-14 2019-08-22 大阪有機化学工業株式会社 耐熱性且つ易剥離性の硬化樹脂膜を形成するための硬化性樹脂組成物及びその製造方法
KR20210082454A (ko) * 2018-09-25 2021-07-05 카듀리온 파마슈티칼스, 인크. 아미노피리미딘 화합물
WO2020068846A1 (en) * 2018-09-25 2020-04-02 Heterocyclic Compound Heterocyclic compound
WO2020187292A1 (zh) * 2019-03-19 2020-09-24 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
CN116685325A (zh) 2020-10-20 2023-09-01 豪夫迈·罗氏有限公司 Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2024097394A1 (en) 2022-11-03 2024-05-10 Denali Therapeutics Inc. Solid and co-crystal forms of a pyrimidine triazole compound
WO2024112746A1 (en) 2022-11-22 2024-05-30 Denali Therapeutics Inc. Processes and intermediates for the preparation of a pyrimidine aminopyrazole compound
CN115819405A (zh) * 2022-12-20 2023-03-21 沪渝人工智能研究院 嘧啶氨基吡唑衍生物及其作为富亮氨酸重复激酶2抑制剂的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100876069B1 (ko) * 2000-09-15 2008-12-26 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
RU2340611C2 (ru) * 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
AU2005322855B2 (en) * 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
EP2440548A1 (en) * 2009-06-10 2012-04-18 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
CN105837519A (zh) * 2010-06-04 2016-08-10 霍夫曼-拉罗奇有限公司 作为lrrk2调节剂的氨基嘧啶衍生物
WO2012031004A1 (en) * 2010-09-01 2012-03-08 Gilead Connecticut, Inc. Pyridinones/pyrazinones, method of making, and method of use thereof
RS56583B1 (sr) * 2010-11-10 2018-02-28 Genentech Inc Derivati pirazol aminopirimidina kao lrrk2 modulatori
US8637537B2 (en) * 2011-08-25 2014-01-28 Genentech, Inc. Serine/threonine kinase inhibitors
CA2853967A1 (en) * 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity
SI3321262T1 (sl) * 2012-03-01 2021-04-30 Array Biopharma, Inc. Inhibitorji serin/treonin kinaze
DK2900657T3 (da) * 2012-09-26 2020-05-04 Hoffmann La Roche Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
KR102002265B1 (ko) * 2013-05-01 2019-07-19 에프. 호프만-라 로슈 아게 바이헤테로아릴 화합물 및 이의 용도

Also Published As

Publication number Publication date
KR20150016532A (ko) 2015-02-12
EP2844652A1 (en) 2015-03-11
CN106220615A (zh) 2016-12-14
JP2015515966A (ja) 2015-06-04
US9212173B2 (en) 2015-12-15
MX2014012945A (es) 2015-02-10
EP2844652B1 (en) 2019-03-13
BR112014026952A2 (pt) 2017-06-27
KR102091894B1 (ko) 2020-03-20
CA2870049A1 (en) 2013-11-07
US20150051238A1 (en) 2015-02-19
WO2013164321A1 (en) 2013-11-07
BR112014026952A8 (pt) 2021-06-15
RU2014147381A (ru) 2016-06-27
CN104271569A (zh) 2015-01-07
BR112014026952B1 (pt) 2022-03-15
CA2870049C (en) 2020-12-29
JP6218808B2 (ja) 2017-10-25
CN104271569B (zh) 2016-08-24
MX363118B (es) 2019-03-11
RU2637947C2 (ru) 2017-12-08

Similar Documents

Publication Publication Date Title
HK1200820A1 (zh) 作為 調節劑的吡唑氨基嘧啶衍生物
HRP20160771T1 (hr) Derivati aminopirimidina kao modulatori za lrrk2
HK1187605A1 (zh) 作為 調節劑的吡唑氨基嘧啶衍生物
HK1210778A1 (zh) 嘧啶吡唑基衍生物
EP2863914A4 (en) PYRAZOLYL DERIVATIVES AS SYK INHIBITORS
HK1200819A1 (zh) 作為 調節劑用於治療帕金森病的吡唑氨基嘧啶衍生物
HK1191862A1 (zh) 吡唑衍生物
HK1213253A1 (zh) 新型吡唑衍生物
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
HUE038700T2 (hu) Benzofuran-2-szulfonamid származékok, mint kemokinreceptor-modulációk
GB201219289D0 (en) Pyrazole derivatives
GB201219296D0 (en) Pyrazole derivatives
GB201218245D0 (en) Pyrazole derivatives
GB201207694D0 (en) Mirror mate
AU2012901406A0 (en) Multi-Fuel System